The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2018
Filed:
Feb. 14, 2014
Applicant:
The Regents of the University of Michigan, Ann Arbor, MI (US);
Inventors:
Zaneta Nikolovska-Coleska, Ann Arbor, MI (US);
Chenxi Shen, Beijing, CN;
Jay Hess, Ann Arbor, MI (US);
Assignee:
The Regents of the University of Michigan, Ann Arbor, MI (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/551 (2006.01); C07D 243/10 (2006.01); A61K 45/06 (2006.01); C07K 7/06 (2006.01); G01N 33/574 (2006.01); C07K 14/82 (2006.01); A61K 31/352 (2006.01); A61K 31/437 (2006.01); A61K 31/4402 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/5513 (2006.01); A61K 38/08 (2006.01); C07D 213/74 (2006.01); C07D 261/20 (2006.01); C07D 311/76 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/06 (2013.01); A61K 31/352 (2013.01); A61K 31/437 (2013.01); A61K 31/4402 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 31/5513 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); C07D 213/74 (2013.01); C07D 261/20 (2013.01); C07D 311/76 (2013.01); C07D 405/04 (2013.01); C07D 409/04 (2013.01); C07D 519/00 (2013.01); C07K 14/82 (2013.01); G01N 33/57426 (2013.01); C07K 2319/00 (2013.01); G01N 2500/02 (2013.01);
Abstract
The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.